Company: PTPI
Filing Date: 2025-01-24
Form Type: S-1
Source: 0001410578-25-000047
Chunk: 20

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-01-24
Form: S-1
Chunk 20
---
 Stockholder Approval is obtained, without the prior written consent of Dawson James Securities, Inc. For more information, see “Plan of Distribution” on page 70 of this prospectus. |
| Market for common stock                            |     | Our common stock is listed on The Nasdaq Capital Market under the symbol “PTPI.”                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Listing of Pre-Funded Warrants and Series Warrants |     | We do not intend to list the Pre-Funded Warrants or either of the Series Warrants on any securities exchange or nationally recognized trading system. Without a trading market, the liquidity of the Pre-Funded Warrants and Series Warrants will be extremely limited.                                                                                                                                                                                                                                                                                                                                                                                       |

The number of shares of our common stock to be outstanding after this offering is based on 11,319,039 shares of our common stock outstanding as of January 22, 2025, and excludes the following:

| ● | 8,106,821 shares of common stock issuable upon exercise of the Company’s outstanding warrants at an average weighted exercise of $13.62 per share; |

10

| ● | 420,133 shares of common stock underlying outstanding stock options of the Company, with a weighted average exercise price of $4.77 per share; |

| ● | 252,378 shares of common stock issuable upon conversion of the 567.85 shares of the Company’s Series A Convertible Preferred Stock (“Series A Preferred Stock”) outstanding, at a conversion price of $2.25 per share, which excludes any Make-Whole Amounts (as defined in the Certificate of Designations), any Additional Amounts (as defined in the Certificate of Designations), any Late Charges (as defined in the Certificate of Designations) and any accrued dividends thereon; and |

| ● | 2,247,658 shares of common stock reserved for issuance under the Company’s Amended and Restated 2020 Omnibus Incentive Compensation Plan (the “Plan”). |

Except as otherwise indicated, all information in this prospectus assumes no exercise of the outstanding warrants, no shares of our common stock are issued pursuant to outstanding stock options and no shares of common stock are issued pursuant to our Plan described above. The discussion above assumes no exercise of Pre-Funded Warrants or Series Warrants in this offering.

11

<div align='center'>**Risk Factors**</div>

Investment in our securities, including our common stock, Series Warrants, and Pre-Funded Warrants, involves a